Callitas Health Inc.

Equities

MPHMF

CA13125C1068

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:05:17 2024-03-01 am EST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	+9,900.00%

2018	James Thompson to Assume the Position of President and Chief Executive Officer of Callitas Health Inc	CI
2018	Callitas Health Inc. Announces Management Changes	CI

M Pharmaceutical Inc. (DB:T3F1) cancelled the sale of Remaining Oil and Gas Assets.

February 18, 2016 at 11:00 pm EST

M Pharmaceutical Inc. (DB:T3F1) entered into an agreement to sell Remaining Oil and Gas Assets for CND 0.25 million on February 19, 2015.

M Pharmaceutical Inc. (DB:T3F1) cancelled the sale of Remaining Oil and Gas Assets on February 19, 2016.

Latest news about Callitas Health Inc.

James Thompson to Assume the Position of President and Chief Executive Officer of Callitas Health Inc	18-06-07	CI
Callitas Health Inc. Announces Management Changes	18-01-03	CI
M Pharmaceutical Inc. Appoints Gary Thompson as President and CEO	17-02-13	CI
M Pharmaceutical Inc. announced that it expects to receive CAD 0.7 million in funding	16-04-05	CI
M Pharmaceutical Inc. Appoints Brian Keane as Interim President and CEO	16-04-04	CI
M Pharmaceutical Inc. Announces Resignation of Mathew Lehman as President, CEO and from the Board of Directors	16-03-15	CI
M Pharmaceutical Inc. (DB:T3F1) cancelled the sale of Remaining Oil and Gas Assets.	16-02-18	CI
M Pharmaceutical, Inc. Announces Resignation of Martin Mintchev from the Board of Directors and as Chief Scientific Officer	15-12-15	CI
M Pharmaceutical Inc. (DB:T3F2) entered into letter of intent to acquire reformulated orlistat for weight loss from Chelatexx, LLC for CAD 1.30 million.	15-11-19	CI
M Pharmaceutical In Acquisition Talks	15-09-21	CI
M Pharmaceutical Inc. Announces Management Changes	15-08-19	CI
M Pharmaceutical Inc. to Open a Fully Owned Subsidiary in Sofia, Bulgaria	15-08-18	CI
Rishena Enters Into Manufacturing Supply Agreement for Production of Trimtec Gastric Stimulation Device	15-08-17	CI
M Pharmaceutical Inc. Appoints Oliver Frank Bathe to its Advisory Board	15-07-17	CI
M Pharmaceutical Inc. announced that it expects to receive CAD 0.35 million in funding.	15-07-06	CI
M Pharmaceutical Inc. (DB:T3F1) completed the acquisition of Trimtec Biomedical Inc.	15-06-25	CI
M Pharmaceutical Inc Appoints Dr. Michel Fattouche to Advisory Board	15-06-19	CI
M Pharmaceutical Inc. Appoints Orly Yadid-Pecht to its Advisory Board	15-06-17	CI
M Pharmaceutical Inc. Appoints Christopher Andrews to Board of Directors	15-05-14	CI
M Pharmaceutical Inc. (DB:T3F1) entered into an agreement to acquire Trimtec Biomedical Inc.	15-05-06	CI
Callitas Health Inc. Auditor Raises 'Going Concern' Doubt	15-04-28	CI
M Pharmaceutical Inc. Announces the Appointment of Dr. Martin Mintchev as President & Chief Executive Officer	15-04-14	CI
M Pharmaceutical Inc. (DB:T3F1) entered into an agreement to sell Remaining Oil and Gas Assets for CND 0.25 million.	15-02-18	CI
M Pharmaceutical Inc. (DB:T3F1) completed the acquisition of the intellectual property associated with the eMosquito device by the purchase of M Diagnostics Inc.	15-02-18	CI
M Pharmaceutical Inc. announced that it has received CAD 1.08 million in funding.	15-02-12	CI

Chart Callitas Health Inc.

Duration

Period

More charts

Company Profile

Callitas Health Inc is a Canada-based company that is primarily engaged in integrated clinical-stage pharmaceutical development and over-the-counter (OTC) consumer goods marketing. The Company provides biomedical technologies and products. The Company offers drug treatments for obesity, infertility, intimacy issues, weight management, female sexual dysfunction solutions and women wellness.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CALLITAS HEALTH INC.	+9,900.00%	4.53K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research